Immunotherapy of multiple sclerosis: The end of the beginning

Current Opinion in Immunology

Volumn 13, Issue 5, 2001, Pages 597-600

  Steinman, L ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; BETA INTERFERON; BETA1A INTERFERON; CORTICOSTEROID; CYTOKINE; DNA VACCINE; ETANERCEPT; GADOLINIUM; GAMMA INTERFERON; GLATIRAMER; IMMUNOLOGIC AGENT; INTEGRIN; INTERFERON BETA SERINE; INTERLEUKIN 12; LENERCEPT; LIGAND; LYMPHOTOXIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; METHYLPREDNISOLONE SODIUM SUCCINATE; MITOXANTRONE; MYELIN BASIC PROTEIN; MYELIN BASIC PROTEIN LIGAND; NATALIZUMAB; OSTEOPONTIN; RECOMBINANT CYTOKINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

CLINICAL TRIAL; DISEASE CONTROL; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; ENCEPHALOMYELITIS; HUMAN; HYPERSENSITIVITY REACTION; MULTIPLE SCLEROSIS; NONHUMAN; OPTIC NERVE DISEASE; RELAPSE; REMISSION; REVIEW; TH1 CELL; TH2 CELL; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0035480052     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(00)00266-1     Document Type: Review

References (25)

1. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III Multiple Sclerosis Study Group
2. Interferon beta-1b is effective in relapsing-remitting MS. 1. Clinical results of a multicenter, randomized, double-blind, placebo controlled trial
3. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis
4. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in MS
5. Effect of early interferon treatment on conversion to definite multiple sclerosis: A randomised study
6. Preventing MS?
7. The effect of corticosteroids for acute optic neuritis on the subsequent development of MS
8. Assessment of the utility of animal models for multiple sclerosis and demyelinating disease in the design of rational therapy
9. Multiple sclerosis: A two stage disease
10. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin
11. Antibodies to CD44 and integrin alpha 4, but not L-selectin, prevent CNS inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment
12. The adhesion molecule and cytokine profile of MS lesions
13. The effect of anti-4 integrin antibody on brain lesion activity in MS
14. Induction of a non-encephalitogenic Th2 autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo controlled, randomized phase II trial
15. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand
16. Specific immunotherapy: One size does not fit all
17. Association between TNF-α and disease progression in patients with MS
18. TNF is a potent anti-inflammatory cytokine in autoimmune mediated demyelination
19. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2
20. TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study
21. Inhibition of IL-12 production in human monocyte-derived macrophages by TNF
22. Chronic tumor necrosis factor alters T-cell responses by attenuating T-cell receptor signaling
23. Role of cytokines in rheumatoid arthritis
24. Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune disease via deviation to the Th2 pathway